Solara Pharma Q2 revenue up 33%, EBITDA more than doubles

Solara Pharma Q2 revenue up 33%, EBITDA more than doubles. Company reported ₹4,178 crore revenue and ₹769 crore EBITDA in Q2 FY27, marking its best quarter in five years. Strong performance driven by robust demand in key geographies and improved margins. Growth signals turnaround in operational efficiency and market positioning.

📊 STOCKS: $SOLARA | 🏢 SECTOR: Pharma | #HIGHIMPACT #Earnings